Inactive Instrument

INSYS Therapeutics, Inc.

Equities

Motion for Asset Sale Approved for INSYS Therapeutics, Inc.

August 23, 2019 at 12:00 am EDT

The US Bankruptcy Court gave an order approving the sale of certain assets of INSYS Therapeutics, Inc. on August 23, 2019. The debtor has been authorized to sell certain assets to Chilion Group Holdings US, Inc. for a purchase price of $12.2 million. The debtor’s assets include assets relating to CBD formulations, Dyndros and Buprenorphine. Chilion Group Holdings US, Inc. submitted the highest bid after the bidding procedures.

Latest news about INSYS Therapeutics, Inc.

INSYS Therapeutics, Inc.'s Equity Buyback announced on November 5, 2015, has expired.	20-03-30	CI
INSYS Therapeutics, Inc. Went Out of Business	20-02-17	CI
Bankruptcy Judge Changed for INSYS Therapeutics, Inc.	20-02-05	CI
Second Motion for Exclusivity Period Extension Approved For INSYS Therapeutics, Inc.	20-01-21	CI
Modified Second Amended Liquidation Plan Approved for INSYS Therapeutics, Inc.	20-01-16	CI
Renaissance Lakewood, LLC completed the acquisition of certain assets of INSYS Therapeutics, Inc. (OTCPK:INSY.Q).	19-12-18	CI
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-12-16	CI
Second Amended Disclosure Statement Approved for INSYS Therapeutics, Inc.	19-12-04	CI
Renaissance Lakewood, LLC entered into an asset purchase agreement to acquire certain assets of INSYS Therapeutics, Inc. (OTCPK:INSY.Q) for $0.28 million.	19-12-02	CI
Second Amended Liquidation Plan And Disclosure Statement Filed by INSYS Therapeutics, Inc.	19-11-29	CI
First Amended Liquidation Plan Filed by INSYS Therapeutics, Inc.	19-11-14	CI
First Motion for Exclusivity Period Extension Approved For INSYS Therapeutics, Inc.	19-11-04	CI
Chilion Group Holdings US, Inc. completed the acquisition of Assets from INSYS Therapeutics, Inc. (OTCPK:INSY.Q) for $12.3 million.	19-10-30	CI
INSYS Therapeutics, Inc. Announces Resignation of Andrew G. Long, Chief Executive Officer, Board of Directors, Effective November 8, 2019	19-10-25	CI
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-10-16	CI
First Motion for Exclusivity Period Extension Filed by INSYS Therapeutics, Inc.	19-10-07	CI
Motion for Case Conversion Filed for INSYS Therapeutics, Inc.	19-09-25	CI
Pharmbio Korea Co., Ltd. agreed to acquire certain assets of Insys Therapeutics, Inc.	19-09-24	CI
Insys Therapeutics : Drugmaker Insys wins bankruptcy court approval to sell off opioid	19-09-19	RE
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-09-19	CI
Joint Liquidation Plan and Disclosure Statement Filed by INSYS Therapeutics, Inc.	19-09-17	CI
BTcP Pharma, LLC entered into an asset purchase agreement to acquire Fentanyl sublingual spray product from INSYS Therapeutics, Inc.	19-09-02	CI
Hikma Pharmaceuticals USA Inc. completed the acquisition of Naloxone And Epinephrine Nasal Sprays from INSYS Therapeutics, Inc. (OTCPK:INSY.Q).	19-08-28	CI
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-08-23	CI
Motion for Asset Sale Approved for INSYS Therapeutics, Inc.	19-08-22	CI

Chart INSYS Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Sector

More about the company